Company intelligence / Profile preview

Yarrow Bioscience

New York, New York, United States

Ownership: Public · YARW
Development stage: Other

Overview

Clinical-stage company with lead program YB-101 in Phase 1b/2b development for Graves' disease in the US, with Phase 1 trial for thyroid eye disease being conducted in China by partner GenSci. Announced a definitive merger agreement with VYNE Therapeutics Inc. in December 2025, expected to close in Q2 2026, and secured $200 million in pre-closing financings. Phase 1b data expected in second half of 2027.

Therapeutic areas: Endocrinology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Shanghai Scizeng Medical Technology (GenSci subsidiary) - global ex-China licensing agreement for YB-101Changchun GeneScience Pharmaceutical

Financials

Market cap: $503.8K
Total revenue: $97K
Enterprise value: $-22.4M

Beyond the preview

Go deeper on Yarrow Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yarrow Bioscience.

Explore the full profile